Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRISM 2

Financiado

Cerrado

Psychiatric Ratings using Intermediate Stratified Markers 2

The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug deve... ver más

30/11/2024

RIJKSUNIVERSITEIT...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

RIJKSUNIVERSITEIT GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 18 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-11-30

IMI2-2020-22-01: Restricted Call to maximise impact...

I+D

Cerrada hace 4 años

0% 50% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

18 Participantes

RIJKSUNIVERSITEIT GRONINGEN

1.02M€ | Lider

BIOTRIAL

174.69K€ | Participante

BIOTRIAL RESEARCH

N.D. | Participante

BIOTRIAL NEUROSCIENCE

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CODIP Cortical Disorganization in Psychosis. Neurophysiological... 222K€ Cerrado

PGC2018-098876-B-I00 ESTUDIOS ELECTROFISIOLOGICOS DEL LENGUAJE Y DE LA COGNICION... 61K€ Cerrado

TRIP Translational Research into Psychiatric disorders genetics... 714K€ Cerrado

GACPD Next Generation Sequencing to Identify Genes Underlying Extr... 100K€ Cerrado

PRISM Psychiatric Ratings using Intermediate Stratified Markers... 16M€ Cerrado

CNS2023-144038 Herramientas diagnósticas, pronósticas y terapéuticas 384K€ Cerrado

Duración del proyecto: 42 meses Fecha Inicio: 2021-05-19
Fecha Fin: 2024-11-30

Líder del proyecto

RIJKSUNIVERSITEIT GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug development. To test whether a quantitative biological approach to the understanding and classification of neuropsychiatric disorders is both feasible and useful the PRISM 1 consortium was formed by academics, SMEs, patient organizations, regulators, ECNP, and EFPIA partners. PRISM 1 has now successfully identified quantitative biological parameters related to diagnosis (Schizophrenia (SZ) and Alzheimer Disease (AD)) as well as to social functioning irrespective of diagnosis. From the relationships between social function, neuroimaging, and cognitive endpoints a new neurobiological framework has emerged now needing further validation. Genetic studies of social functioning outcomes revealed known and novel loci for this phenotype. In addition, a preclinical test battery was developed, based on homologs of the clinical paradigms, to allow effective back-translation and a deepening of our neurobiological knowledge. Finally, a novel digital tool for assessing social function provided a novel, objective characterization that transcended the initial diagnostic classification and the digital readouts were associated with other study parameters. To build on outcomes of PRISM 1, PRISM 2 has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD that emerged from PRISM 1 and determine its potential to generalise to Major Depressive Disorders. Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. Third, to translate and communicate project results to the benefit of stakeholders, such as regulators, patients and their families, and health care providers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores